Inhaled Corticosteroids

Oral candidiasis from an inhaler isn't a sign of infection spreading — it's a preventable nursing failure. The intervention takes 30 seconds and changes everything.

Inhaled corticosteroids (ICS) like fluticasone, budesonide, and beclomethasone deposit medication in the oropharynx, suppressing local immune defenses. The most common adverse effect is oropharyngeal candidiasis (thrush) — white patches on the tongue and buccal mucosa. Prevention is straightforward: rinse the mouth and spit after every dose. Using a spacer with a metered-dose inhaler reduces oropharyngeal deposition and lowers thrush risk. Dysphonia (hoarseness) is the second most common local effect, caused by direct steroid deposition on the larynx leading to mucosal irritation and vocal cord changes. Systemically, ICS at standard doses carry minimal risk, but long-term high-dose use can cause adrenal suppression, decreased bone mineral density, growth suppression in children (monitor height), and easy bruising. The nurse monitors for signs of systemic absorption: round face, weight gain, hyperglycemia. Patients must understand that ICS are not rescue inhalers and stopping abruptly after prolonged high-dose use risks adrenal crisis.

Key Distinctions

Don't confuse ICS-induced thrush (white patches, preventable with rinsing) with oral infection requiring antibiotics — thrush from ICS is treated with antifungals like nystatin. Students mix up local side effects (thrush, hoarseness) with systemic effects (adrenal suppression, osteoporosis), which only emerge at high doses over months. Rinsing and spitting is for ICS specifically — students incorrectly generalize this to all inhalers including bronchodilators.

Clinical Pearl

Rinse, gargle, spit — never swallow. If the patient skips this step after every ICS dose, expect to see white patches within weeks.

Use & Administration

Inhaled corticosteroids (ICS) — including fluticasone, budesonide, and beclomethasone — are the cornerstone controller therapy for persistent asthma. They work by suppressing airway inflammation at the local level: ICS inhibit the release of inflammatory mediators (cytokines, leukotrienes, prostaglandins) and reduce mucosal edema, mucus hypersecretion, and bronchial hyperresponsiveness over time. This is NOT a rescue mechanism. ICS do not produce bronchodilation and will not relieve an acute attack. Onset of therapeutic benefit takes 1–2 weeks of consistent daily use, with maximum benefit at 4–8 weeks. The patient must use ICS every day on schedule — even when feeling well — because the drug prevents inflammation rather than reversing it in the moment. ICS are also used as maintenance therapy in moderate-to-severe COPD, typically combined with a long-acting bronchodilator. When both a bronchodilator and ICS are prescribed via separate inhalers, the bronchodilator is used first to open airways, followed by the ICS so the steroid penetrates deeper into the lungs.

Key Distinctions

Don't confuse controller therapy (ICS, taken daily to prevent symptoms) with rescue therapy (SABA like albuterol, used for acute bronchospasm). Students often think ICS work immediately — they don't; the 1–2 week delay is highly testable. Don't confuse inhaled corticosteroids with systemic corticosteroids like prednisone; ICS deliver medication locally with minimal systemic absorption, which is exactly why they're preferred for long-term use.

Clinical Pearl

Bronchodilator before corticosteroid — open the door, then deliver the medicine. And ICS every day, not just on bad days.